Full-Time
Senior Director/Vice President
Delivery
Posted on 6/27/2024
Orbital Therapeutics
51-200 employees
Develops RNA-based medicines and therapies
Expert
Cambridge, MA, USA
- Ph.D. in Biochemistry, Chemical Engineering, Biology, or related scientific discipline.
- A proven scientific leader with 10+ years of industry experience.
- Familiarity with delivery of nucleic acids is required.
- Experience in moving technology from preclinical to clinical stages.
- Outstanding teamwork, communication, and interpersonal skills.
- Team leadership experience with a demonstrated track record of personnel development.
- Ability to adapt to increasing scope and complexity of work brought on by growth/change and helps others manage through change.
- Provide leadership and strategic direction for delivery at Orbital.
- Lead design and synthesis of novel chemical libraries to enhance delivery of nucleic acids in lipid nanoparticles.
- Engage with CDMOs to successfully scale lead compounds.
- Develop with expert scientists virus like particles (VLP) delivery technology.
- Optimize delivery of nucleic acids using either LNP or VLP delivery technologies.
- Work closely with IP to assess patentability, develop patent strategy and lead preparation of patent applications & documents.
- Communicate scientifically rigorous findings and delivery strategy via verbal and written communications, including internal presentations to key stakeholders (e.g. Executive leadership team, Board of Directors) and external presentations.
- Lead, teach and mentor junior staff to promote a culture of growth and learning.
Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology, advanced delivery methods, data science, and automation to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, allowing it to carve out a unique niche in the genetic medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these medicines to healthcare providers, who then administer them to patients.
Company Stage
Series A
Total Funding
$320M
Headquarters
San Francisco, California
Founded
2022
6 month growth
↑ 21%1 year growth
↑ 19%2 year growth
↑ 294%
Simplify's Take
What believers are saying
- Securing $270 million in Series A financing provides substantial capital to advance their RNA-based therapeutic platform.
- The company's focus on next-generation vaccines, immunomodulation, and protein replacement positions it at the forefront of innovative treatments for various diseases.
- Strategic partnerships, such as with Beam Therapeutics, enhance Orbital's capabilities in RNA and delivery technologies, broadening their therapeutic applications.
What critics are saying
- The highly competitive field of RNA-based medicines requires continuous innovation to maintain a leading position.
- The complexity of developing and commercializing RNA-based therapies could lead to longer timelines and higher costs.
What makes Orbital Therapeutics unique
- Orbital Therapeutics focuses exclusively on RNA-based medicines, excluding small interfering RNA, which sets it apart from other genetic medicine companies.
- The company leverages a unique combination of RNA technology, delivery methods, data science, and automation to create a versatile platform for developing a broad range of medicines.
- The leadership team, including Dr. Giuseppe Ciaramella, brings extensive experience in drug discovery and biotherapeutics, providing a strategic advantage in the competitive landscape.
Help us improve and share your feedback! Did you find this helpful?